Healthcare Biz Recap: Amarin’s PROSPECTS, Lincare Waits for PROPOSAL
Shares of Amarin Pharmaceuticals (NASDAQ:AMRN) jump as U.S. patent examiners seem set to okay a line of key patents which could protect its AMR101 prescription fish oil pill from generic competition through the year 2030. Jefferies is confident of approval, restating its Buy on the shares and boost its target price from $24 to $26.
Don’t Miss: Arena SHOOTS THE MOON on Epic Approval.
Lincare Holdings (NASDAQ:LNCR) shares react in kind to reports that the company’s suitors, which includes Germany’s Linde AG (LANGF.PK) are making offers presently. The firm supplies oxygen and other respiratory services to in-home patients.
Shares of PM Synergetics (NASDAQ:SURG) soar after hours with word that it’s received FDA clearance for VersaVIT, which constitutes a vitrectomy system for the retinal surgery market.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.